Trevi Therapeutics Inc(TRVI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.34 | Insider Own | 27.67% | Shs Outstand | 142.4M | Perf Week | 7.53% |
| Market Cap | 1.93B | Forward P/E | - | EPS next Y | -27.9% | Insider Trans | -0.1% | Shs Float | 103.0M | Perf Month | -4.37% |
| Enterprise Value | 1.61B | PEG | - | EPS next Q | -0.13 | Inst Own | 81.87% | Short Float | 15.53% | Perf Quarter | -24.25% |
| Income | -0.05B | P/S | - | EPS this Y | -50.26% | Inst Trans | 12% | Short Ratio | 8.26 | Perf Half Y | -2.24% |
| Sales | 0.00B | P/B | 6.01 | EPS next 5Y | - | ROA | -18.97% | Short Interest | 16.01M | Perf YTD | 8.31% |
| Book/sh | 2.26 | P/C | 6.06 | EPS past 3/5Y | 11.11% 29.44% | ROE | -19.66% | 52W High | -32.94% ($20.22) | Perf Year | 21.4% |
| Cash/sh | 2.24 | P/FCF | - | Sales past 3/5Y | - | ROIC | -15.88% | 52W Low | 38.09% ($9.82) | Perf 3Y | 640.98% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 18.54% | Gross Margin | - | Volatility(W/M) | 4.55% 5.26% | Perf 5Y | 1054.04% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.64 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 37.28 | EPS Q/Q | -20.34% | Profit Margin | - | RSI (14) | 50.67 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 37.28 | Sales Q/Q | - | SMA20 | 5.47% ($12.86) | Beta | 1.14 | Target Price | $29.5 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -7.7% ($14.69) | Rel Volume | 0.89 | Prev Close | $13.81 |
| Employees | 34 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -0.46% - | SMA200 | -5.46% ($14.34) | Avg Volume(3M) | 1.94M | Price | $13.56 |
| IPO | 2019/5/7 | Option/Short | Yes/Yes | Trades | 12004 | Volume | 1,732,009 | Change | -1.81% |
A US clinical-stage biotech company developing therapeutics for respiratory-related diseases such as chronic cough. It is developing oral drug candidates targeting chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough, and has a lead candidate in late-stage clinical development. It is a differentiated respiratory biotech targeting the chronic cough area, which has significant unmet medical needs.
Over the past 1 year, roughly in the middle
33% below its 1-year high.
Traded about as much as usual. That is 89% of its average volume.
TRVI has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -50.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +1054.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 81.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #105 of 597 in the industry
Based on market cap of $2B.
BRVE#103 Braveheart Bio Inc $2B PER - 
COAG#104 Hemab Therapeutics Holdings Inc $2B PER - TRVI#105 Trevi Therapeutics Inc $2B PER - 
VIR#106 Vir Biotechnology Inc $2B PER - 
ABSI#107 Absci Corp $2B PER - 
FAQ
What kind of company is TRVI?
TRVI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of TRVI?
The market cap of TRVI is approximately $1.9B, ranking 2,071 within its sector.
What is the 52-week high and low for TRVI?
TRVI has recorded a 52-week high of $20.22 and a low of $9.82.
